We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: TDI-132 Shows Promising Results in the Treatment of ALS
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > TDI-132 Shows Promising Results in the Treatment of ALS
BusinessNewsPublic Health

TDI-132 Shows Promising Results in the Treatment of ALS

HerinaAyot
HerinaAyot
Share
3 Min Read
SHARE

ALS may be the most deadly disease many people have never heard of.

ALS may be the most deadly disease many people have never heard of. Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig’s disease affects at least 30,000 people in the United States and 450,000 people worldwide.  It is a progressive neurodegenerative disorder that causes muscle atrophy, paralysis, and ultimately death with a three to five year survival rate.

While the incidence rate of ALS is similar to that of Multiple Sclerosis (MS) with 5,000 new cases per year, more people die from ALS because there are virtually no effective treatments.

Founded in 1999 by the Heywood family, the ALS Therapy Development Institute seeks to provide an urgent response to the crisis that is ALS.  Dr. Steve Perrin, ALS TDI’s CEO and CSO, spearheads the development of computational biology capabilities and information management systems to more clearly understand the molecular mechanisms associated with disease onset and progression in neurodegenerative diseases.

More Read

The Importance Of Medical Labels And Supplement Labels
Expect Modest Growth in Health Spending through 2013
Musings on 2012 Health IT
Should We Tax Fat?
Saving Money: Paying Cash for Health Care Even If You’re Insured

A non profit organization, ALS TDI collaborates with biotech and pharma companies to address the unmet need in neurodygeneration.

In ALS, nerve cells (neurons) waste away or die, and can no longer send messages to muscles. This eventually leads to muscle weakening, twitching, and an inability to move the arms, legs, and body. The condition slowly gets worse. When the muscles in the chest area stop working, it becomes hard or impossible to breathe on one’s own.

ALS TDI is in phase II clinical trials with two drugs, one of which has previously been approved by the FDA to treat MS and is marketed by Novartis. Gilenya, or TDI 132, blocks lymphocytes in blood and has shown promising results in mice, on several disease measures.

ALS TDI operates on a $10M annual budget with zero funding from NIH. Much of their funding is derived from CRO relationships, foundations, and individual donors.

Dr. Perrin presented the company’s drugs and technologies at the BIO CEO & Investor Conference in New York February 12-13.

 

TAGGED:ALSLou Gehrig's diseaseTDI
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026
Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026

You Might also Like

Why Pilot Projects Don’t Work

January 4, 2012
Hospital Marketing, Digital Marketing, Video Marketing, Online Marketing
BusinessSocial Media

Why Video Matters in Hospital Marketing

August 25, 2014

Ebola: Chronicle of a Debacle Foretold

October 24, 2014
hospital marketing job
BusinessFinanceHospital Administration

How to Protect Your Hospital Marketing Job and Career

September 19, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?